Navigation Links
Phidea Srl and Marvin Research Srl Announce Completion of Merger
Date:1/22/2009

MILAN, Italy, January 22 /PRNewswire/ -- Phidea S.r.l. a full service and leading clinical research organization (CRO), today announced that it has completed the merger with Marvin Research S.r.l., a CRO focused on Phase I to Phase IV clinical trials.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080122/335477 )

The new company will be named Phidea Marvin S.r.l. and have legal and operating offices in Milan, Italy. The combined company will also continue to operate its offices in Madrid, Spain providing drug development services to companies in need of a single source for clinical research including design and management of pan-European clinical trials (Phase I - III), and post marketing studies (Phase IV). Services offered by the new company will include all aspects of the clinical trial process including: protocol design, regulatory affairs, site selection, clinical monitoring, data management, statistical analysis and medical writing. Observational and epidemiological studies will also continue to be performed.

Phidea Marvin specializes in cardiovascular, CNS, gastroenterology oncology, rheumatology and anti-infective studies and services a broad range of multinational pharmaceutical firms.

Vincenzo Cocuzza, M.D., Phidea-Marvin's Chief Executive Officer stated, "We believe that this combination broadens our client base even further then it was, and provides the necessary platform for growth. We have a compelling strategy to expand operations into global markets and especially the United States and will continue to look for strategic opportunities that allow us to realize our goals. The merger with Marvin moves us closer to our objectives by:

    - Adding a partner with a strong market position and reputation in
      specific therapeutic areas

    - Adding additional multinational customers

    - Reducing costs

    - Increasing the overall size of the organization to allow even larger
      studies to be performed.

We also believe that the Marvin and Phidea teams have built an impressive portfolio of accomplishments and will work together to become a leader in the CRO sector."

About Phidea S.r.l.

Phidea S.r.l. specializes in international clinical research. The firm was founded in 1982 in Milan, Italy. In 1991 it expanded its operations and organized its Spanish subsidiary, Phidea Spain, in Madrid, Spain. The firm and partners provide a complete range of services to pharmaceutical companies including product formulation, stability, clinical trial material manufacturing, and all phases of clinical research.

Staffed with renown scientist and medical doctors, Phidea services major pharmaceutical companies seeking premium research in the European Union.

About Marvin Research S.r.l.

Marvin Research was founded in January 1999 by Vincenzo Maresca, M.D., with a team of experts from several CROs. Based in Milan, Italy, the firm focuses on Phase I through Phase IV human clinical trials for multinational pharmaceutical companies. Marvin Research's services span the entire clinical program including preparation of protocols by medical experts, all aspects of monitoring and performance of the trial, and finally statistics and report generation.

    Phidea Marvin Management Team.

    Vincenzo Cocuzza, Chairman and CEO
    Vincenzo Maresca, Managing Director
    Aldo Cocuzza, Managing Director

    For more information regarding Phidea Marvin S.r.l. contact:

    Mr. Aldo Cocuzza, Director,
    +39-3939189389 or email at aldo.cocuzza@phideamarvin.com

    Phidea-Marvin S.r.l.
    International Clinical Research
    Via Cristoforo Colombo, 1.
    Corsico (Milan, Italy)




'/>"/>
SOURCE Phidea Marvin Srl
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Stents Can Treat - Not Just Prevent - Strokes, Suggests Early Research
2. Inclinix Releases Next Generation Critical Population Research(R) (CPR) for Clinical Trial Investigator Site Selection and Patient Recruitment
3. Beactica Announces Fragment-Based Drug Discovery Research Collaboration With GE Healthcare and Uppsala University
4. WaferGen and University of Texas Southwestern Medical Center Establish Biomarker Research Collaboration for SmartChip(TM) Real-Time PCR System
5. Michael J. Fox Foundation Awards $2.7 Million to Four Industry Teams for Pre-Clinical Parkinsons Disease Research
6. Fertility Physicians of Northern California Researchers Test New Forms of Progesterone Medication for Luteal Support During IVF
7. 2008 Human Research Protection Award Recipients Announced
8. New Research Reveals Unforeseen Side Effect of the Breast Cancer Movement
9. K-State Researcher Finds Correlation Between Childhood Obesity and Asthma
10. Myeloperoxidase Research Expands
11. Research Highlights New Approaches to Prevent Blood Clots in Several High-Risk Patient Populations Including Largest Study Ever to Examine Use of Blood-Thinning Medication in Patients With Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... , Feb. 8, 2016 Vestagen Technical Textiles, ... performance apparel for healthcare and other demanding applications, today ... Executive Officer. He replaces Dale Pfost , PhD, ... Mr. Bold is also joining Vestagen,s Board of Directors. ... class of active barrier technologies that combines fluid repellent, ...
(Date:2/8/2016)... RICHMOND, Calif. , Feb. 8, 2016 /PRNewswire/ ... leader in therapeutic genome editing, announced that the ... the Company,s Investigational New Drug (IND) application for ... a life-long therapy for Mucopolysaccharidosis Type I (MPS ... and enables Sangamo to initiate a Phase 1/2 ...
(Date:2/5/2016)... , Feb. 5, 2016  Despite the recent explosion ... than other industries to embrace Big Data due to ... On the medical side, organizations have begun looking to ... clinical trials to adherence. --> ... firm Best Practices, LLC, Big Data has started informing ...
Breaking Medicine Technology:
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... TopConsumerReviews.com recently ... in Mole removal products. , Moles are derived from a cluster of melanin when ... all the wrong places and create a lifetime of embarrassment. Historically, mole removal ...
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... Guruji Mahendra ... 9th, 10th and 11th, 2016 in honor of his birthday on February 10th. ... happiness. Mahendra Trivedi is known by over 250,000 people from over 40 different ...
(Date:2/8/2016)... ... February 08, 2016 , ... According to research by the ... dental technicians to be certified or obtain continuing education. To increase patient awareness ... In Your Mouth?” campaign to inform dentists and patients about the possible lack ...
(Date:2/7/2016)... Orion, Clarkston, Metamora, Michigan (PRWEB) , ... February 07, 2016 , ... ... Friday in recognition of National Wear Red Day. National Wear Red Day is ... and stroke in women. Heart disease and stroke cause 1 in 3 deaths among ...
(Date:2/7/2016)... ... 2016 , ... Dr. Todd Hobgood , certificated in ... surgical expertise. Technically known as deoxycholic acid or previously as ATX-101, Kybella® ... for reduction of fat below the chin (aka the “double chin”). Medication side ...
Breaking Medicine News(10 mins):